Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5469754 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| RO5469754 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Single doses, iv or sc |
| RO5469754 | DRUG | Single ascending doses, iv or sc |
Inclusion Criteria: * Healthy male or female volunteers, 18 to 64 years of age, inclusive * Body mass index (BMI) 18 to 32 kg/m2 * Women of child-bearing potential and their partners must be willing to use two highly effective forms of contraception, one of which must be a barrier method, for the e...
RO5469754 is an investigational small molecule being developed by Roche Holding AG (RHHBY). It is currently in Phase 1 clinical development, studied in healthy volunteers. The drug is not approved and remains under investigation.
RO5469754 is being studied for use in healthy volunteers as part of early clinical research. Its purpose is to evaluate the safety, tolerability, and pharmacokinetics of the drug in humans. It is not yet approved for any medical condition.
RO5469754 is being developed by Roche Holding AG, a multinational healthcare company traded under the ticker RHHBY. Roche is conducting clinical trials to evaluate the drug's safety and tolerability in healthy volunteers.
RO5469754 is in Phase 1 clinical development. A single-ascending-dose study in healthy volunteers has been completed. The drug remains investigational and has not received regulatory approval.
RO5469754 has one completed Phase 1 trial, NCT01620931, titled "A Single-Ascending-Dose Study of RO5469754 in Healthy Volunteers." The study enrolled 36 participants in the Netherlands and was placebo-controlled, though not double-blinded.
No alternative names for RO5469754 have been identified. The drug is known by its developmental code name RO5469754 and is being studied by Roche Holding AG.